GT Biopharma Doses First Patient in GTB-5550 Trial
GT Biopharma announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550, its B7-H3-targeted natural killer (NK) cell engager for solid tumors expressing B7-H3.
